key: cord-1052223-1etsqku7
authors: King, J. T.; Yoon, J. S.; Bredl, Z. M.; Habboushe, J. P.; Walker, G. A.; Rentsch, C. T.; Tate, J. P.; Kashyap, N. M.; Hintz, R. C.; Chopra, A. P.; Justice, A. C.
title: Accuracy of the Veterans Health Administration COVID-19 (VACO) Index for predicting short-term mortality among 1,307 Yale New Haven Hospital inpatients and 427,224 Medicare patients
date: 2021-01-04
journal: nan
DOI: 10.1101/2021.01.01.20249069
sha: 9884919ffcd63a5643e125a75ca15dc7415c76b8
doc_id: 1052223
cord_uid: 1etsqku7

Background: The Veterans Health Administration COVID-19 (VACO) Index incorporates age, sex, and pre-existing comorbidity diagnoses readily available in the electronic health record (EHR) to predict 30-day all-cause mortality in both inpatients and outpatients infected with SARS-CoV-2. We examined the performance of the Index using data from Yale New Haven Hospital (YNHH) and national Medicare data overall, over time, and within important patient subgroups. Methods and findings: With measures and weights previously derived and validated in a national Veterans Healthcare Administration (VA) sample, we evaluated the accuracy of the VACO Index for estimating inpatient (YNHH) and both inpatient and outpatient mortality (Medicare) using area under the receiver operating characteristic curve (AUC) and comparisons of predicted versus observed mortality by decile (calibration plots). The VACO Index demonstrated similar discrimination and calibration in both settings, over time, and among important patient subgroups including women, Blacks, Hispanics, Asians, and Native Americans. In sensitivity analyses, we allowed component variables to be re-weighted in the validation datasets and found that weights were largely consistent with those determined in VA data. Supplementing the VACO Index with body mass index and race/ethnicity had no effect on discrimination. Conclusion: Among COVID-19 positive individuals, the VACO Index accurately estimates risk of short-term mortality among a wide variety of patients. While it modestly over-estimates risk in recent intervals, the Index consistently identifies those at greatest relative risk. The VACO Index could identify individuals who should continue practicing social distancing, help determine who should be prioritized for vaccination, and among outpatients who test positive for SARS-CoV-2, indicate who should receive greater clinical attention or monoclonal antibodies.

The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) has prioritized those 75 years and older and those 65-74 years of age with "high risk" medical conditions for novel coronavirus (COVID-19) vaccination [1] .

However, these criteria identify a large proportion of the US adult population. A more tailored risk estimation incorporating specific age and pre-existing conditions could facilitate multiple objectives including: 1) motivating high risk individuals and their contacts to practice social distancing until vaccinated, 2) identification of individuals testing positive at drive up sites who require clinical examination and possibly laboratory evaluation, 3) prioritization for early outpatient monoclonal antibodies, and 4) prioritization for vaccination.

outcomes, but just a small subset have developed and prospectively validated predictive models in large samples. Most of these require data available only at acute presentation (symptoms, exam findings, diagnostic imaging, or laboratory data). We find four published, internally validated, predictive models for COVID-19 mortality based exclusively on pre-existing conditions that might address the applications discussed above. The United Kingdom QCOVID model is based on a national sample of 8.25 million individuals, but concatenates testing positive, a rapidly changing risk largely dependent on ever changing local prevalence, and 8 We report the AUC and calibration plots as assessments of the VACO Index performance and of alternative models in all three datasets. We used the VACO Index coefficients to calculate a predicted mortality for each patient in the YNHH and Medicare datasets, and then determined AUCs for the early and later testing dates, and in important subgroups: age (<65 vs 65+, except in Medicare data), sex (male vs female), race/ethnicity (Black vs non-Black), and US census region (except in YNHH data), and compared the values to those obtained in the original VACO Index development cohort. We refit models using the VACO Index variables in the VA, YNHH and Medicare datasets to understand how the model might have differed had it been developed in alternative datasets. To assess the impact of race and BMI, we also refit models supplementing VACO Index variables with race (VA, YNHH, and Medicare) and BMI (VA, YNHH -BMI is unavailable in Medicare data).

We assessed calibration plots of observed versus predicted 30-day mortality in ten (VA and Medicare data) or five (small sample size: YNNH data, VA female) strata containing equal numbers of deaths, in early and later testing cohorts and in subgroups by age, sex, race/ethnicity, and US census region. Data analyses were performed using Stata, version 15.1 (StataCorp, College Station, TX) and SAS 9.4 (SAS Institute Inc, Cary, NC). This study was conducted in compliance with the Health Insurance Portability and Accountability Act and was approved by the Institutional Review Boards of VA Connecticut Healthcare System and Yale University, both of whom granted waivers of consent. This cohort study is reported according to the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) guidelines (S1. Checklist) [12] .

for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.01.20249069 doi: medRxiv preprint

The dataset included 13,323 (VA), 1,307 (YNHH) and 427,224 (Medicare) patients for a total of 441,854 COVID-19 patients (Table 1 ). Compared to VA (median age 63 years) and YNHH (median age 65 years), Medicare patients (median age 78 years) were older. A higher proportion of Medicare patients were White (75%) compared to YNHH (44%) and VA (39%).

YNHH had the largest proportion of Hispanic patients (21%). Women were better represented in YNHH (52%) and Medicare (58%) than in VA (9%). BMI was missing in 7% of VA patients and 22% of YNHH patients, and median BMI values were similar in VA (30.1 kg/m 2 ) and YNHH (29.5 kg/m 2 ) cohorts and unavailable in Medicare. Consistent with the older age of the Medicare cohort, most comorbid conditions were substantially more common, with a few exceptions: AIDS (2%) and mild liver disease (10%) were most common in VA data, and myocardial infarction was most common in YNHH (14%). Medicare patients were much less likely to have a Charlson Comorbidity Index score of zero indicating no comorbid disease (17%) versus VA (32%) or YNHH (47%).

In comparing early versus later testing period patients (Table 1) , a greater proportion in the later period were in the youngest age strata of 20-49 years in both VA (early 19.5% vs later 27.1%) and YNHH (early 18.9% vs later 23.3%). A larger proportion were Hispanic in the later period in VA (early 11.0% vs later 13.8%), YNHH (early 20.2% vs later 21.2%), and Medicare (early 3.5% vs later 3.8%). Fewer in the later period were Black in VA (early 51.5% vs later 38.3%), YNHH (early 31.5% vs later 30.7%) and Medicare (early 20.2% vs later 13.1%). In Medicare, the proportion of Asians decreased (early 2.7% vs later 2.4%) and Native North Americans nearly doubled (early 0.4% vs later 0.7%). Across datasets, the proportion with for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We compared unadjusted ORs estimated in each cohort among all adult COVID-19 patients in VA and YNHH (Table 2a) This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The VACO Index demonstrated good discrimination in YNHH data overall (AUC: 0.80, 95% CI: 0.77 -0.83), consistent with that seen in VA overall (AUC: 0.82, 95% CI: 0.81 -0.83) (Table 3a) . Discrimination in YNHH early and later periods were similar to the VA development period (Table 3a) . When AUCs were estimated for subgroups, the VACO Index demonstrated similar discrimination in YNHH data as in VA data among those <65 years of age, those 65 and over, men, Non-Hispanic Black patients, Hispanic patients and Other race/ethnicity patients. The 

Restricting all cohorts to the age range included in Medicare (65 years or older), the VACO Index demonstrated consistent AUCs in VA and Medicare data (Table 3b ). In all cases, for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.01.20249069 doi: medRxiv preprint 12 the AUCs estimated within Medicare data fell within the 95% CI for the VA AUCs overall and by testing date, gender, b race/ethnicity and census region.

When comparing the age-restricted VA and Medicare calibration plots, there was evidence of modest over prediction in both samples (Figures 2a and b) . Of note, the Index slightly under-estimated risk in the early interval of Medicare data but was better calibrated among Black, Hispanic, Asian, and North American Native than among White patients.

Compared to the original VACO Index (Table 4, 

Based on age, sex and pre-existing conditions, the VACO Index maintains good discrimination and calibration for short-term mortality among patients with COVID-19 in two demographically diverse samples outside the VA healthcare system. While unadjusted associations between specific variables and mortality vary by database, adjusted associations identified in VA data are largely consistent in YNHH and Medicare data, demonstrating that for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.01.20249069 doi: medRxiv preprint relative weights assigned variables in the VACO index are reasonably consistent with the weights that would be assigned with YNHH or Medicare data. These findings suggest that COVID-19 mortality associations seen in VA data generalize reasonably well to other United States populations. Additionally, even though mortality rates have decreased over time, the index effectively discriminates those at greater and lesser risk of mortality in both time periods within all three samples. This is true regardless of patient sex, race/ethnicity, or region of the country.

The VACO index demonstrates that while age is a major driver of COVID-19 mortality, comorbid disease burden quantified by Charlson Comorbidity Index further stratifies risk. The

Charlson Comorbidity Index has several strengths in its use as a summary measure of comorbid disease. First, it has been widely demonstrated to be associated with health outcomes in general [13, 14] and specifically in COVID-19 [15] . Second, it can be assessed using EHR data, administrative data, or direct patient interview [13, 16] . Third, the Charlson Comorbidity Index accounts for differences in severity of disease processes by weighting metastatic cancer, AIDS, severe liver disease and diabetes with complications more heavily than other conditions. Fourth, the Charlson Comorbidity Index offers stable weights for conditions that likely contribute to the comorbid disease burden for an individual, but are less common, e.g., rheumatological conditions. When we evaluated whether separately modeling each of the 17 conditions included in the Charlson Comorbidity Index or the Charlson Index score was a better predictor, the AUC in models using the individual conditions were improved by 0.01. However, the weighting assigned to the individual conditions varied more across cohorts than did the weighting assigned the Charlson Index score (data not otherwise shown). Thus a model fit to individual conditions would be less likely to generalize well to new data.

for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.01.20249069 doi: medRxiv preprint Given the ready accessibility of the VACO Index on MDCalc, we anticipate several immediate applications. The VACO Index may be important for those 60-74 years of age who may both be at substantial risk and often remain employed. In fact, 39% of those age 60-74 in the US are employed [17], thus accurate personalized risk estimation can better inform personal and system level decisions regarding return to work or other group settings. Another important question is how to manage the majority of those undergoing testing in drive up settings. A follow-up phone call to notify the individual that they are positive currently entails a few questions about fever and shortness of breath. If neither are present the patient is advised to quarantine for 2 weeks. However, some of these individuals may be at high risk for serious illness or mortality, justifying a more complete clinical evaluation incorporating vital signs, diagnostic imaging, and laboratory tests. As vaccines and therapeutic options may be in limited supply, the VACO Index could help health systems and government agencies develop a datadriven approach to allocating resources to those at greatest risk of mortality who are most likely to benefit.

Minority populations experienced a greater burden of infection in the beginning of the pandemic [18], leading to suggestions that overall population risk may seem a more equitable criteria for vaccine prioritization. However, modeling population risk of mortality from COVID-19 encompasses two distinct components: probability of infection (infection detection dependent on access to testing and probability of a positive test), and probability of dying once infected.

The associations between risk factors such as age, race, and ethnicity are very different for being tested, testing positive, and mortality [18] . The geographic distribution of the pandemic has shifted rapidly over time and testing positive is a volatile outcome that has fluctuated with local disease prevalence. Early in the pandemic in the Spring of 2020 those living in US urban centers for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.01.20249069 doi: medRxiv preprint on the East and West coasts were at greatest risk of infection. Over time, the pandemic surged in the Midwest and South and extended to rural settings. The second wave of the pandemic in Autumn and Winter of 2020 has largely generalized, with increased infections among Whites and younger individuals. We have demonstrated that risk of mortality after infection has been more stable over time than who is tested and who tests positive. Over the next 6-12 months, nearly everyone not immunized or previously infected is at risk of infection. Thus, we argue that the best strategy is to prioritize those at greatest risk of mortality if infected.

Given the growing debate over the roles of BMI and race/ethnicity in COVID-19 outcomes, we carefully investigated their associations with mortality in our data. Including BMI in the index did not improve the discrimination of the Index as a whole in any of the three data sets in our study. A prospective cohort study of 1,150 COVID-19 inpatients [19], a retrospective cohort of 1,687 inpatients in New York City [20], and a retrospective registry of 331 COVID-19 patients in Italy [21] also did not find an independent association between obesity and mortality.

However, in an analysis of 6,916 SARS-CoV-2 positive inpatients and outpatients, Tartof et al. did find higher relative risk of death among obese patients [22] . The study authors comment that this increased risk is not uniform across different populations, as the association between high BMI was strong in younger adults ≤ 60 and males. Results from the American Health Association COVID-19 Cardiovascular Disease Registry [23] also had similar findings where they found obese patients to be at higher risk of COVID-19 mortality, notably among adults <50 years and weakly in >70 years. The difference with our findings may be due to the older patient population studied in our samples (VA and Medicare), as age is a major driver in mortality risk, and the number of comorbidities that can account for risk increases with age.

for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.01.20249069 doi: medRxiv preprint Adding race/ethnicity to the VACO Index did not improve the accuracy of the predictions. Further, associations with race/ethnicity varied among the cohorts, with Black race and Hispanic ethnicity associated with reduced risk of mortality in VA and YNHH data and increased risk among Medicare patients. Since race and ethnicity are largely proxies for socioeconomic disparities [24], it is not surprising that their association with mortality among those testing positive for SARS-CoV-2 is variable. National VA data frequently demonstrates fewer disparities by race in health outcomes than outside VA, likely due to reduced economic barriers to care and national efforts to ensure quality of care [25, 26] . YNHH is a tertiary care academic hospital that draws from Southern Connecticut and Western Rhode Island. In contrast, national Medicare data encompasses widely diverse medical facilities, and minority patients are more likely to be cared for in lower quality facilities [27, 28]. While we considered offering an adjustment for race/ethnicity to be applied outside VA, we are concerned that adding race/ethnicity would introduce substantial noise in the risk estimation due to variation in association across facilities and would confuse biology and socio economics [24, 29] .

Importantly, the VACO Index demonstrated consistent or better accuracy in racial and ethnic minority patients as in White patients.

The discrimination of the VACO Index quantified by AUC in Medicare patients was lower than in VA or YNHH patients overall. This discrepancy is related to the reciprocal relationship between the proportion of outcomes events in a population and AUC -all else equal, the AUC will be higher in populations where the outcome is less common [30, 31] . Similarly, when a variable such as age is a major driver of risk, restricting the population tested to a particular age group (e.g., 65 years and over) will result in a constrained AUC [30, 31].

Importantly, the AUC was highly consistent in patients 65 years and over across the three for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.01.20249069 doi: medRxiv preprint samples and calibration curves in Medicare data demonstrated good agreement between observed and expected mortality rates across diverse races and ethnicities.

Vaccine supply will be limited over the next 6-12 months. We will need a reasonable approach to prioritizing vaccinations in the general population. To minimize lives lost in a generalized epidemic we should vaccinate those at greatest risk of mortality first. The VACO Index shows that for individuals under the age of 85 years, burden of comorbid disease substantially differentiates risk of mortality. For example, a 55-year-old male with a Charlson Comorbidity Index of 10 and peripheral vascular disease has the same mortality risk as an average 65-year-old.

There are limitations to our study. While we were able to evaluate the index in a national sample of over 427,000 people over the age of 65, our ability to validate in substantially younger patients remains somewhat limited. None of the Medicare sample, only 25% of the VA sample, and 20% of the YNHH samples were under 50 years of age. However, the most pressing questions concerning vaccine allocation are focused on individuals over 50 years of age. Also, our calibration is based on mortality events occurring before August 2020 when mostly symptomatic patients were being tested. The VACO Index may over-estimate risk of mortality among asymptomatic patients and this will require further study. Nevertheless, the VACO Index represents the most widely validated risk index for short term mortality from COVID-19. This standardized and validated index can supplement clinical judgement to help inform patient management and health policy.

for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.01.20249069 doi: medRxiv preprint Figure 1b . Calibration plots comparing VACO Index predicted and observed 30-day mortality in Veterans Health Administration (VA) and Yale New Haven Health (YNHH) data in Non-Hispanic White vs Non-Hispanic Black and Hispanic subgroups, and in early (March 2 to April 15, 2020) vs later (April 16 -July 19, 2020) testing date subgroups. The dashed diagonal line represents perfect prediction. Values above the dashed line indicate overprediction of mortality by the VACO Index, and values below the line represent underprediction. Error bars depict 95% confidence intervals of mortality predictions. Small sample size of YNHH data limited subgroup plots to five strata and produced wide confidence intervals.

for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.01.20249069 doi: medRxiv preprint Figure 2a . Calibration plots comparing VACO Index predicted and observed 30-day mortality in Veterans Health Administration (VA) patients age 65 and older and Medicare data, overall and in sex and early (March 2 to April 15, 2020) vs later (April 16 -July 19, 2020) testing date subgroups. The dashed diagonal line represents perfect prediction. Values above the dashed line indicate overprediction of mortality by the VACO Index, and values below the line represent underprediction. Error bars depict 95% confidence intervals of mortality predictions -large sample size of Medicare data produced tight 95% confidence intervals that are not visible at this plot scale. Small VA female sample size limited plots to five strata.

for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.01.20249069 doi: medRxiv preprint Figure 2b . Calibration plots comparing VACO Index predicted and observed 30-day mortality in Veterans Health Administration (VA) patients age 65 and older and Medicare data in race/ethnicity subgroups: Non-Hispanic White, Non-Hispanic Black, Hispanic, Asian, and North American Natives (the latter two categories only available in Medicare data). The dashed diagonal line represents perfect prediction. Values above the dashed line indicate overprediction of mortality by the VACO Index, and values below the line represent underprediction. Error bars depict 95% confidence intervals of mortality predictions -large sample size of Medicare data produced tight 95% confidence intervals that are not visible at this plot scale.

for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.01.20249069 doi: medRxiv preprint Figure 3 . Forest plot of multivariable models of COVID-19 30-day mortality. VACO Index original model includes age, sex, Charlson Comorbidity Index and age interaction term, and myocardial infarction (MI) or peripheral vascular disease (PVD). Veterans Health Administration (VA) data model refits VACO Index variables and adds body mass index (BMI) and race (Non-Hispanic White, Non-Hispanic Black, Hispanic, Other). Yale New Haven Health (YNHH) data model refits VACO Index variables and adds BMI and additional race categories (Non-Hispanic White, Non-Hispanic Black, Hispanic, and Other). Medicare data model refits VACO Index variables, and adds BMI and race (Non-Hispanic White, Non-Hispanic Black, Hispanic, Asian North American Native, and Other). Models and odds ratios of most variables are consistent across the datasets, providing evidence of the generalizability of the VACO Index model.

for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ;

The Advisory Committee on Immunization Practices' interim recommendation for allocating initial supplies of COVID-19 Vaccine -United States

Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study

Personalized predictive models for symptomatic COVID-19 patients using basic preconditions: hospitalizations, mortality, and the need for an ICU or ventilator